Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
OncoMed Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01277146
First received: January 6, 2011
Last updated: September 16, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)